Story · Medicine & Biotech

Fei Shen: Can KLK2 and PSMA Targeting Open New Doors in Prostate Cancer Treatment?

1 outlet · first reported by OncoDaily 1d ago

Coverage, in order

  1. 1d ago
    OncoDaily obscure
    Fei Shen: Can KLK2 and PSMA Targeting Open New Doors in Prostate Cancer Treatment?

    Fei Shen, Director, Global Compound Development Team Leader (CDTL) at Johnson & Johnson, shared on LinkedIn: “Very proud to see the first-in-human results for pasritamig + JNJ-9401 (PSMAxCD28) presented at

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.